Prophylaxis with apixaban feasible for cancer patients

March 29, 2012
Prophylaxis with apixaban feasible for cancer patients
Primary venous thromboembolism prophylaxis with apixaban, an oral direct Factor Xa inhibitor, in ambulatory cancer patients undergoing first- or second-line chemotherapy for advanced or metastatic cancer, is safe and well tolerated, according to a phase II study published online March 12 in the Journal of Thrombosis and Haemostasis.

(HealthDay) -- Primary venous thromboembolism prophylaxis with apixaban, an oral direct Factor Xa inhibitor, in ambulatory cancer patients undergoing first- or second-line chemotherapy for advanced or metastatic cancer, is safe and well tolerated, according to a phase II study published online March 12 in the Journal of Thrombosis and Haemostasis.

Mark N. Levine, M.D., of McMaster University in Hamilton, Canada, and colleagues conducted a randomized phase II trial of oral apixaban in patients with advanced or metastatic lung, breast, gastrointestinal, bladder, ovarian, myeloma, or . Subjects receiving either first- or second-line chemotherapy were randomized to 5 mg (32 patients), 10 mg (30 patients), or 20 mg (33 patients) once a day of apixaban or placebo (30 patients) for 12 weeks. Administration of the study drug began within four weeks of chemotherapy initiation.

The researchers found that there were no major bleeds for those taking 5 mg or 10 mg apixaban, two major bleeds among patients taking 20 mg, and one major bleed in the . The corresponding numbers of clinically relevant non-major bleeds were one, one, two, and zero. There was a 2.2 percent rate of major bleeding in the apixaban patients, with no fatal bleeds. Three patients in the placebo group had symptomatic venous thromboembolism (VTE).

"These results support further study of apixaban in Phase III trials to prevent VTE in cancer patients on chemotherapy," the authors write.

The study was funded by Bristol-Myers Squibb and ., which manufacture apixaban; two authors are employed by Bristol-Myers Squibb.

Explore further: Apixaban superior to warfarin for preventing stroke, reducing bleeding and saving lives

More information: Abstract
Full Text (subscription or payment may be required)


Related Stories

Recommended for you

Study examines evolution of cancer

February 8, 2016

A novel Yale study answers age-old questions about how cancers spread by applying tools from evolutionary biology. The new insights will help scientists better understand the genetic origins of tumor metastases, and lead ...

The growing menace of HPV‑related throat and mouth cancers

February 2, 2016

There's a new cancer epidemic on the rise. It's an aggressive throat and mouth cancer caused by the human papillomavirus (HPV)—the same sexually transmitted virus that leads to cervical cancer—but it's affecting mostly ...

How gut inflammation sparks colon cancer

February 4, 2016

Chronic inflammation in the gut increases the risk of colon cancer by as much as 500 percent, and now Duke University researchers think they know why.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.